The Institute of Cancer Research, London
More than £5 million secured for the ICR from Cancer Research UK’s RadNet programme to fund work in radiotherapy. Cancer Research UK has awarded The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust a substantial £5.14 million through its radiation research network (RadNet) to support pioneering research in radiation therapy.
About Us - The Institute of Cancer Research, London
At the ICR we are researching how to treat the differences between cancers – an approach known as personalised medicine. The ICR is led by Chief Executive Professor Kristian Helin, known for his pioneering scientific discoveries in cancer epigenetics. We are world leaders in identifying cancer genes, discovering cancer drugs and developing ...
Our Research - The Institute of Cancer Research, London
The Institute of Cancer Research, London, has been driving scientific discoveries on cancer and its treatment for more than 100 years. We are internationally renowned for our work into cancer genetics, cancer biology and personalised medicine – and came second of all UK universities in analysis of the 2021 Research Excellence Framework.
Researchers and Groups - Institute of Cancer Research
Honorary Faculty Dr Merina Ahmed. Professor Susana Banerjee Dr Peter Barry Dr Shreerang Bhide Ricky Bhogal Dr Kevin Boyd Declan Cahill Dr Geoff Charles-Edwards Professor Ian Chau Dr Julia Chisholm Dr Irene Chong Professor David Cunningham Dr Dimitra Darambara Dr Claire Dearden Professor Glenn Flux Dr Nicos Fotiadis Dr Angela George Professor Andrew Hayes
Clinical trials - The Institute of Cancer Research, London
The Institute of Cancer Research, London, has a strong track record in progressing research from bench to bedside through state-of-the art clinical trials. From first-in-human studies to large multicentre trials, we’re committed to delivering innovative, practice-changing clinical trials, particularly to assess the latest precision treatments.
About our research - The Institute of Cancer Research, London
About our research. Cancer is a highly complex disease with more than 200 types, each caused by a different combination of genetic defects. Even among patients with a single type of cancer, such as breast or lung cancer, the genetic triggers vary from one person to the next. At The Institute of Cancer Research, London, we believe it is ...
Breast cancer - The Institute of Cancer Research, London
Clinical trials. We led trials establishing the effectiveness of the chemotherapy drug carboplatin – discovered at the ICR – in triple-negative breast cancer, and of the targeted drug palbociclib in advanced, metastatic breast cancer.. Recently, results from the OlympiA trial showed that using the targeted drug olaparib to treat some women with early stage breast cancer and mutations in ...
Studying and Training - The Institute of Cancer Research, …
Training students to carry out cutting-edge cancer research in one of the eight research divisions at the ICR. Developing future leaders in clinical cancer research and supporting the translational work of the ICR and partners. Teaching medically qualified candidates about the latest developments in cancer research and clinical practice.
Our strategy - The Institute of Cancer Research, London
Our strategy. New ICR strategy: Defeating cancer. Our vision: We will transform the lives of cancer patients through world-class research and education, and by growing our impact on society. Video: ICR Chief Executive Kristian Helin gives an overview of our new five-year strategy. Cancer patients are living longer and with a better quality of life.
ICR ranked as one of world’s top research institutes for influence and ...
The Institute of Cancer Research is one of the top-ranked higher education institutions in the world for academic influence and commercial impact, according to an international assessment.. We ranked ‘excellent’ – the top mark available – in 10 separate categories in this year's 2021 U-Multirank report, an annual independent evaluation funded by the European Commission.